Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.
Viruses like influenza A and Ebola invade human cells in a number of steps. In an interdisciplinary approach, research teams from Heidelberg University and Heidelberg University Hospital investigated the final stages of viral penetration using electron tomography and computer simulations.
The body’s biological clock is interfered with by abnormal sleep habits, such as those of night shift workers, which have been connected to lung health problems.
Researchers found that, despite being heavily immunocompromised, hematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.
In the future, vaccines may be delivered with a puff of air rather than a needle, according to the promising results of new research presented at a meeting of the American Chemistry Society this March.
Influenza viruses have an enormous impact in the U.S., with an estimated 25 million illnesses and 18,000 deaths in the 2022-23 flu season alone.
A new software tool developed by Texas Biomedical Research Institute and collaborators can help scientists and vaccine developers quickly edit genetic blueprints of pathogens to make them less harmful.
The majority of what scientists know about viruses in animals comes from the list of nucleotides that constitute their genomic sequence, which, although useful, provides relatively few signals about a virus’ propensity to infect people.
A new study led by researchers at Harvard Medical School illuminates how the brain becomes aware that there is an infection in the body.
On March 2, BGI's Multiplex Real-time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2, Influenza A Virus and Influenza B Virus obtained market access qualification to enter the Australian Register of Therapeutic Goods.
Experts from the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Aragon Nanoscience and Materials Institute of Aragon (INMA) -;a joint institute of the CSIC and the University of Zaragoza-; have developed a new method to detect RNA viruses based on the triplex-forming probe technology.
A study conducted by researchers at the University of Liège on group 2 innate lymphoid cells (or ILC2s) shows that the functional reprogramming of these cells following their exposure to viruses allows our body to react differently to exposure to certain respiratory allergens.
A new University of California, Irvine-led study uncovers how a protein, APOBEC3B, could protect cells against many different types of RNA viruses like respiratory syncytial virus (RSV), SARS-CoV2, influenza virus, poliovirus and measles, helping to prevent disease.
A new grant of over $17 million from the National Institute of Allergy and Infectious Diseases (NIAID) has established La Jolla Institute for Immunology (LJI) as the leading institute for human immunology data curation, analysis, and dissemination. With this funding, LJI has taken the helm of the Human Immunology Project Consortium Data Coordinating Center, a critical tool in the effort to fuel scientific collaboration in immunoprofiling and highlight findings from the overall Human Immunology Project Consortium (HIPC).
Jon Jacobs, a biochemist, has examined the blood of people suffering from diseases including Ebola, cancer, TB, hepatitis, diabetes, Lyme disease, brain damage, and influenza.
Viruses use the molecular repertoire of the host cell to replicate. Researchers from the Cluster of Excellence ImmunoSensation2 at the University of Bonn, together with Japanese researchers, want to exploit this for the treatment of influenza.
Cambridge scientists have created a novel test that “fishes” for many respiratory viruses at once using single strands of DNA as “bait” and provides extremely accurate results in under an hour.
Although it frequently necessitates a challenging laboratory procedure, the quantitative detection of specific antibodies in complex samples like blood can provide information on a variety of diseases.
As the COVID-19 pandemic demonstrated, potentially harmful new viruses can spread throughout the population long before the system for monitoring global public health can catch them.
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.
The structure of the influenza replication machinery and how it interacts with cellular proteins have been solved by a team of Oxford University scientists using a variety of techniques at Diamond Light Source.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.